Welcome to our dedicated news page for MiMedx Group (Ticker: MDXG), a resource for investors and traders seeking the latest updates and insights on MiMedx Group.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect MiMedx Group's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of MiMedx Group's position in the market.
Rhea-AI Summary
MiMedx Group, Inc. (Nasdaq: MDXG) received a FDA Warning Letter for AXIOFILL classification, not related to safety. The company submitted a Request for Designation for AXIOFILL to the FDA, expecting 2023 net sales growth in the high teens and fourth quarter adjusted EBITDA margin above 20%.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
News
Rhea-AI Summary
MiMedx Group, Inc. (MDXG) announced the automatic conversion of 95,000 shares of Series B Convertible Preferred Stock into approximately 30 million shares of Common Stock. This conversion simplifies the balance sheet, eliminates ongoing dividend payment obligations, and marks an important milestone in the company's journey to improve its financial profile. The company's CEO expressed gratitude towards the partners who provided financial support, highlighting the resources necessary to reshape the company and position it for future growth.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.11%
Tags
-
Rhea-AI Summary
MDXG: MiMedx Group, Inc. Announces Participation in Investor Conferences - MIMEDX senior management to attend Craig-Hallum Capital Group 14th Annual Alpha Select Conference, Mizuho Medical Device & Healthcare Services Summit 2023, and Stifel MedTech 2023 Annual West Coast Bus Tour. Investors can schedule meetings with senior management through respective representatives.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.7%
Tags
Rhea-AI Summary
MiMedx Group, Inc. (Nasdaq: MDXG) will sponsor an Innovation Theater lunch symposium at the Symposium on Advanced Wound Care (SAWC) Fall meeting. The symposium will focus on the clinical and economic impacts of using skin substitutes in the treatment of Venous Leg Ulcers (VLUs) and the impact of adequate debridement in the treatment algorithm of chronic wounds. MiMedx will also participate in the conference's exhibition at booth number 511. Nine clinical and scientific posters have been accepted and will be displayed, showcasing the use of Purion processed human placental allografts.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.62%
Tags
-
Rhea-AI Summary
MiMedx Group, Inc. (Nasdaq: MDXG) reported net sales growth of 20.7% in the third quarter of 2023 compared to the same period last year. The company also announced the launch of EPIEFFECT™, a new product in its Advanced Wound Care portfolio. Additionally, MiMedx repurchased $9.5 million of Series B Preferred Stock held by Hayfin Capital Management, LLP. The company raised its full-year 2023 net sales growth outlook to the high teens.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.8%
Tags
-
Rhea-AI Summary
MiMedx Group, Inc. announces the launch of EPIEFFECT, expanding its portfolio of Advanced Wound Care solutions. EPIEFFECT offers a thick, tri-layer configuration suitable for securing grafts in place with sutures and is a preferable treatment option for deep or tunneling wounds. Customer anticipation for EPIEFFECT is high.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.91%
Tags
Rhea-AI Summary
MiMedx Group, Inc. announces participation in investor conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.47%
Tags
-
Rhea-AI Summary
MDXG: MiMedx Reports 21.5% Increase in Q2 Net Sales, Raises 2023 Guidance, Appoints New CFO. Strong commercial momentum drives net sales growth, increased guidance for 2023. New CFO Doug Rice joins highly accomplished team. Adjusted EBITDA of $14.1 million represents 17.4% of net sales. Company announces strategic realignment, increasing focus on Wound & Surgical businesses.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.9%
Tags
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.53%
Tags
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.42%
Tags
MiMedx Group, Inc
Nasdaq:MDXG
MDXG Rankings
MDXG Stock Data
1.08B
116.20M
3.76%
61.47%
3.52%
Small Arms, Ordnance, and Ordnance Accessories Manufacturing
Manufacturing
United States of America
MARIETTA
About MDXG
mimedx® is an industry leader in advanced wound care and a therapeutic biologics company developing and distributing human placental tissue allografts with patent-protected processes for multiple sectors of healthcare. the company processes the human placental tissue utilizing its proprietary purion® process methodology, among other processes, to produce allografts by employing aseptic processing techniques in addition to terminal sterilization. mimedx has supplied more than two million allografts, through both direct and consignment shipments. for additional information, please visit www.mimedx.com.